India has enrolled its first newborn in the global NeoSep1 trial at JIPMER, Puducherry. The study will test antibiotic ...

The Global Antibiotic Research and Development Partnership (GARDP) said yesterday that an international clinical trial ...

Neonatal sepsis is a leading cause of infant morbidity and mortality in low- and middle-income countries (LMICs), yet despite this, progress in the development and implementation of effective ...

A major multi-country study has found that WHO-recommended first-line antibiotics for neonatal sepsis are likely to be effective in only one-quarter of infections in low- and middle-income countries ...

While we acknowledge the potential benefits of a consensus neonatal sepsis definition for the purpose of interventional trials, this review highlights multiple characteristics of neonatal sepsis that ...

Sepsis is one of the most commonly encountered pathologies in the neonatal intensive care unit (NICU) and is associated with significant morbidity and mortality. 1 Many infants with sepsis develop ...

Sepsis leads to life-threatening organ failure due to dysregulated host responses to infection and presents uniquely across age groups. Neonatal sepsis, affecting infants in their first 28 days, ...

The NeoSep1 trial is expected to enroll 3,000 newborns across Asia and Africa by the end of 2028. ​Along with India, newborns ...

LISBON, Portugal — A shift toward broader-spectrum antibiotics and increasing antibiotic resistance has led to high levels of mortality and neurodevelopmental impacts in surviving babies, according to ...

This may sound like an intimidating technical topic, but I’m going to keep it simple. I went to public schools, so I’m going to leave the complicated math to MIT graduates.[2] Before I dive into the ...

Each year, sepsis affects more than 30 million people worldwide, causing an estimated six million deaths. Sepsis is the body's extreme response to an infection and is often life-threatening. Since ...